First surgical robot capable of bother operating in hospitals and portable in the open field
Post-money valuation ⓘ
$10.2M
As of Oct 2024 · from XSurgical Common Stock 2 · pre-money + amount raised, not a traded price
Total raised
$44,600
Across 2 rounds since 2021
Latest share price
$2.00
XSurgical Common Stock 2 offering price
Financials
FY2019–FY2025 · from SEC filings · hover any figure for its source
$0
−$211K
2019
$0
−$135K
2020
$0
−$11K
2021
$0
−$76K
2022
$0
−$109K
2023
$0
−$56K
2024
$0
−$57K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
$0
Net income
-$210,843
-$134,787
-$11,160
-$76,210
-$108,682
-$56,142
-$56,535
Taxes paid
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$70,170
$2,467
$6,040
$8,179
$9,543
$1,809
$555
Accounts receivable
$0
$0
$15,172
$0
$0
$0
$0
Total assets
$210,170
$132,467
$261,583
$220,179
$194,543
$160,766
$132,569
Short-term debt
$0
$39,412
$0
$320,000
$159,490
$320,000
$0
Long-term debt
$308,438
$323,859
$385,881
$385,881
$245,684
$425,433
$766,705
Total liabilities
$308,438
$363,271
$385,881
$705,881
$405,174
$745,433
$766,705
Other
Headcount
—
1
—
0
0
0
0
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
XSurgical Robotics by XSSurgical Inc Preferred Stock 1
XSurgical Common Stock 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.